Nov 27, 2019 - Top Research Reports for Merck, Eli Lilly & Charter Communications
Nov 20, 2019 - Alkermes (ALKS) submits NDA to the FDA seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder.
Nov 14, 2019 - Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
Nov 08, 2019 - Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.
Nov 06, 2019 - Radius (RDUS) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019 as Tymlos gains traction.
Nov 05, 2019 - Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Nov 04, 2019 - Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.
Nov 04, 2019 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q3 sales
Oct 31, 2019 - Sanofi (SNY) reports mixed third-quarter results with strong Specialty Care sales but soft Vaccines & Consumer Healthcare sales.
Oct 29, 2019 - Incyte (INCY) reports better-than-expected results for the third quarter of 2019, owing to strong Jakafi sales.